Search the Newsreel

Earnings Flash (CAVA) CAVA Group, Inc. Reports Q2 Revenue $365.4M, vs. FactSet Est of $360.1M

CAVA Group, Inc. (CAVA) reported Q2 revenue of $365.4 million, surpassing FactSet's estimate of $360.1 million. This financial beat comes despite broader economic worries and previous outbreaks affecting the restaurant industry, demonstrating the company's strong performance. The news has led to a pre-bell jump …

Avista (AVA) Q2 2026 Earnings Call Transcript

Avista's Q2 2026 earnings call focused primarily on the devastating wildfires near Spokane, Washington, which caused significant damage to their electric and natural gas infrastructure. CEO Heather Rosentrater discussed the company's response, efforts to restore service, and the effectiveness of their wildfire mitigation strategies. …

Avista Plans Leadership Shift as Executive Prepares to Retire

Avista (NYSE: AVA) announced leadership changes effective October 1, 2026, as part of a planned succession strategy. Alicia Gibbs has been appointed Vice President, Growth, Innovation and Strategy, and Patrick Ehrbar has been appointed Vice President, Regulatory Affairs. These changes precede the planned retirement …

AvalonBay Communities (AVB) Faces A Valuation Test, Is An 9% Discount Enough?

AvalonBay Communities (AVB) has experienced recent stock price declines but is considered 8.7% undervalued with a fair value of $201.44 per share, according to Simply Wall St. The valuation is supported by expected long-term undersupply of housing and strong demand in its key markets, …

Earnings live updates: Nebius stock soars as AI cloud revenue jumps 514%, Cava gains on earnings beat

The second quarter earnings season is beginning to wind down, with nearly 90% of S&P 500 (^GSPC) companies having already reported. The takeaway from the quarter so far has been unbridled strength. According to FactSet data, second quarter earnings for S&P 500 companies are …

Cava Group's Second Quarter Earnings Outlook

Analysts predict Cava Group's revenue to grow by 28.3% to $360.1 million in Q2, with GAAP earnings per share increasing from $0.16 to $0.18, showcasing its growth in the fast-casual sector. Despite this, Cava's stock has declined from April highs due to industry pressures …

CAVA Group's Next Earnings Report on Aug. 11 Could Send the Stock Soaring. Here's Why.

Key Points The Mediterranean fast-casual chain has delivered impressive results since it went public in 2023. Young consumers seem to be coming back to fast-casual dining in what's become known as the "little treat economy." Cava is historically cheap at a price-to-sales ratio under …

Why Savaria Corporation stock is sliding today

Datavault AI Inc. Class Action Lawsuit Alert: Johnson Fistel Notifies Investors of October 5, 2026 Lead Plaintiff Deadline

Johnson Fistel, PLLP has announced a class action lawsuit against Datavault AI Inc. (NASDAQ: DVLT) on behalf of investors who purchased securities between September 4, 2024, and October 30, 2025. The lawsuit alleges that Datavault AI made false and misleading statements regarding its business …

Why Avant Brands Inc stock is plummeting today

Theravance Biopharma earnings missed by $0.17, revenue fell short of estimates

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings per share of $0.07, matching analysts' consensus estimates. The company showed a strong return on equity of 18.84% and a net margin of 104.34%. Analysts currently maintain a "Hold" rating on the stock with a consensus price target …

Cavalier Resources (ASX:CVR) Rises As Crawford Gold Development Advances

Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY

Theravance Biopharma reported a Q2 GAAP net loss of USD 5.9 million, a swing from a profit in the prior year, despite an 11% increase in revenue to USD 20.7 million, primarily from the Viatris collaboration. The company also saw reduced R&D and SG&A …

Wall Street Analysts See Cava (CAVA) as a Buy: Should You Invest?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter? Let's …

Is Theravance Biopharma Inc (TBPH) Undervalued After Q2 Earnings

Theravance Biopharma Inc (TBPH) released its Q2 2026 earnings, reporting an 11% increase in YUPELRI collaboration revenue to $20.7 million and a 35% reduction in operating expenses. Despite these gains and a solid cash balance, the company faces challenges, including a failed Phase 3 …

Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M

Theravance Biopharma, Inc. (TBPH) announced its Q2 revenue of $20.7 million, falling short of FactSet's estimate of $22.5 million. The company's stock was trading at 16.90 USD, reflecting a slight dip in performance. Theravance Biopharma specializes in developing and commercializing medicines for respiratory and …

Earnings Flash (TBPH) Theravance Biopharma Posts Q2 Net Loss $0.11 a Share, vs. FactSet Est of $0.07 EPS

Navan Upgrades Singapore Airlines NDC to Direct Connection

Integration brings exclusive fares and enhanced servicing for travelers PALO ALTO, Calif., August 10, 2026--(BUSINESS WIRE)--Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced that it has upgraded its Singapore Airlines NDC access to a direct connection using the carrier's …

Earnings To Watch: Cava Group Inc (CAVA) Q2 2026 -- GF Value Sees 76% Upside

Cava Group Inc (CAVA) is scheduled to release its Q2 2026 earnings on August 11, 2026, with revenue estimates at $361.78 million and earnings at $0.14 per share. Analysts project an average target price of $92.32 for CAVA, suggesting a 47.9% upside, while GuruFocus …

Form 8K Theravance Biopharma Inc For: 10 August By Investing.com

This article announces that Theravance Biopharma Inc. filed a Form 8K on August 10, 2026. The filing is a standard SEC disclosure for significant corporate events. The brief note from Investing.com provides no further details about the content of the 8K.

Theravance's Once-Daily COPD Treatment Posts $70.7M Sales

Theravance Bio: Q2 Earnings Snapshot

Theravance Biopharma Inc. (TBPH) reported a second-quarter loss of $5.9 million, or 11 cents per share. Adjusted earnings were 19 cents per share, while the company's revenue of $20.7 million surpassed analyst expectations of $19.8 million. This financial snapshot highlights their performance in the …

Brava Energia (BRAV3) rescinde acordo de acionistas em meio à mudança de controle para a Ecopetrol

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming clinical results. Halozyme Therapeutics Inc. (HALO) Halozyme is a biopharmaceutical company specializing in the production of proprietary enzymes and devices. …

CAVA Stock Is Flat in 2026, It Reached $95 and Gave It All Back. Here’s Why.

CAVA Group stock is flat in 2026, having twice reached $95 and then fallen back to $62 despite strong revenue growth. The stock's stagnation is attributed to a management outlook that signaled deceleration and large holders selling shares at the $90 peak. While analysts …

Theravance Biopharma (TBPH) Earnings Date and Reports 2026

Is Avient (AVNT) Still Below Fair Value After Strong Earnings And Raised Guidance?

Avadh Sugar & Energy Ltd. Share Price Near 52-Week High

Avarga (SGX:X5N) Stock Rebounds To Profit As One Off Loss Clouds Outlook

Avista (AVA) Earnings Growth And Dividend Keep Fair Value In Focus

Chenavari Toro Income Fund Limited EUR Revenue Breakdown – LSE:TORG

Savara Extends MOLBREEVI Patent Protection to 2041

Savara Inc. has secured patent protection in Europe and Australia for its investigational lung-disease therapy, MOLBREEVI, extending coverage to March 2041. These patents cover the liquid formulation and add to existing protection for the drug-device combination, strengthening the company's intellectual property portfolio in markets …

Avantor, Inc. (AVTR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Avantor, Inc. (NYSE:AVTR) on behalf of shareholders who purchased securities prior to March 5, 2024, and continue to hold them. The investigation focuses on whether Avantor and its officers engaged in corporate wrongdoing. The …

Sei Investments Co. Purchases 92,063 Shares of Avanos Medical, Inc. $AVNS

Avista Corp (AVA) Earnings Forecast: Future EPS & Revenue Growth Estimates